Clinical Trials
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...
August 07, 2026 | News
Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...
August 07, 2026 | News
Ascletis Initiates Global Phase III Trial for Oral GLP-1 Obesity Drug ASC30
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...
August 05, 2026 | News
Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma
Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...
August 05, 2026 | News
MARS Bioimaging Secures First Clinical Sale of Portable Photon-Counting CT System
Christchurch-based Reform Radiology becomes inaugural clinical customer as New Zealand-developed photon-counting CT technology enters routine clinical&nb...
August 05, 2026 | News
GlycoNex Doses First Patient in Phase I Trial of Novel Glycan-Targeting ADC GNX1021
GlycoNex Inc. announced that the first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's nov...
August 04, 2026 | News
From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC
BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...
August 04, 2026 | Interaction
Ractigen's World's First saRNA Therapy for Ocular Diseases Advances to Global Clinical Development Following U.S. FDA IND Clearance
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy f...
August 03, 2026 | News
Thermo Fisher Launches Real-World Registry to Advance Long-Term Vitiligo Research
Thermo Fisher Scientific, the world leader in serving science, announced the launch of the PPD™ CorEvitas™ Vitiligo Registry, a prospective, ob...
July 31, 2026 | News
Medidata Launches AI Layer to Scale Clinical Intelligence Across Global Trial Portfolios
Built on an award-winning AI foundation, Medidata Plus removes traditional barriers, empowering sponsors and CROs to scale intelligence across entire portf...
July 31, 2026 | News
Seegene Advances Comprehensive HPV and STI PCR Testing with Large-Scale Clinical Evidence
STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive case...
July 29, 2026 | News
Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line
One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...
July 28, 2026 | Analysis
OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon
OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device comp...
July 28, 2026 | News
AnHorn Medicines Advances First-in-Class AH-008 into Phase I Trial for Chemotherapy-Induced Neuropathy Prevention
AnHorn Medicines announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotect...
July 27, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
